Bristol-Myers Squibb Company
- BMY
- NYSE
- Drug manufacturers
- Oncology & Hematology
- Immunology & Inflammation
- Cardiovascular & Fibrosis
$58.83
Today −1.54%Quote Oct 19, 2026, 08:00 PM UTC
−6.71%over the last month
Max drawdown −11.3%From 1-month high −7.9%3 months −3.4%
Our viewPro
The call stays with Pro
Verdict, why now, and the write-up open with Pro. New accounts get 14 days of Pro free.
About Bristol-Myers Squibb
Bristol-Myers Squibb Company operates as a global biopharmaceutical entity, actively involved in the research, development, licensing, production, and worldwide commercialization of its medicinal portfolio. The company's therapeutic areas span hematology, oncology, cardiovascular health, immunology, fibrotic conditions, neuroscience, and infectious diseases like COVID-19.
Where the money comes from
Q2 2026 revenue $12.98B
- Eliquis$4.48B34.5%
- Opdivo$2.48B19.1%
- Orencia$1.03B8.0%
- Yervoy$769.0M5.9%
- Reblozyl$735.0M5.7%
- Other Growth Brands$653.0M5.0%
- Breyanzi$484.0M3.7%
- Revlimid$425.0M3.3%
- Camzyos$416.0M3.2%
- Opdualag$349.0M2.7%
- Opdivo Ovantig$261.0M2.0%
- Pomalyst/Imnovid$204.0M1.6%
- Other$687.0M5.3%
Sector
Healthcare
Industry
Drug manufacturers
Exchange
NYSE
Employees
32,500
Founded
1887
Dividend date
Nov 2, 2026
Market value
$120.17B
Quote Oct 19
Floor
$58.24
1.0% below price
Resistance
$59.38
0.9% above price
Price vs analyst targets
42 analysts
Lowest target
$41.00Highest target
$82.00
$41.00Highest target
$82.00
- Price $58.83
- Average target $66.08
- Analysts' target range
Analysts' average target sits about 12% higher. Their range is wide.
The call stays with Pro
7 locked chapters- What to do with this namePro
- Why nowPro
- Why this stockPro
- Section write-upsPro
- Story timelinePro
- News briefPro
- Ask about BMYPro
Verdict, why now, and the write-up open with Pro. New accounts get 14 days of Pro free.
Log in — 14 days free